Aim:To assess the AccuSway PLUS system, which aims to quantify deficiency in human balance, using the measurement of the effect of lorazepam on body sway in healthy volunteers. Methods: A double-blind, randomised, placebo-controlled, two-way crossover study in 12 healthy male and female volunteers. Participants received a single oral dose of lorazepam 2mg and placebo, 1 week apart. Body sway was assessed using the AccuSway PLUS system, by measuring the length of the path of the centre-of-pressure (COP), and the area of the 95% confidence ellipse enclosing the COP (A95). Body sway was assessed at baseline and at 2, 3, 4, 6, 12, 18 and 24 hours after administration, in two positions: with the participants' eyes open and feet apart at hip's width (EOFA), and with their eyes shut and feet together (ESFT). Results: Statistically significant differences in body sway between lorazepam and placebo were detected for up to 18 hours after administration. The largest change in body sway was 2 hours post-dose, in the EOFA position; the mean (95% confidence interval) difference between lorazepam and placebo in fold change of A95 was 7.67 (3.88, 15.17), and in length of COP was 1.61 (1.23, 2.10). Conclusion: The findings confirm that the AccuSway PLUS system is a useful tool for detecting changes in body sway induced by centrally acting drugs.
ORIGINAL RESEARCH ARTICLEInt J Pharm Med 2005; 19 (4): 233-238 1364-9027/05/0004-0233/$34.95/0
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.